199 related articles for article (PubMed ID: 36431875)
21. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer.
Li Y; Sun Z; Cui Y; Zhang H; Zhang S; Wang X; Liu S; Gao Q
Bioorg Chem; 2021 Feb; 107():104636. PubMed ID: 33465670
[TBL] [Abstract][Full Text] [Related]
23. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
[TBL] [Abstract][Full Text] [Related]
24. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.
Lai HH; Lin LJ; Hung LY; Chen PS
Biochem Biophys Res Commun; 2018 Nov; 506(1):87-93. PubMed ID: 30336979
[TBL] [Abstract][Full Text] [Related]
25. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
[TBL] [Abstract][Full Text] [Related]
26. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
27. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
[TBL] [Abstract][Full Text] [Related]
28. Copper (II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells.
Liu Z; Fan L; Niu D; Chen M; Zhang W; Liu Y; Xu J; Wang D
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37503758
[TBL] [Abstract][Full Text] [Related]
29. The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
Yu M; Xu C; Zhang H; Lun J; Wang L; Zhang G; Fang J
Biochem Biophys Res Commun; 2021 Jul; 563():1-7. PubMed ID: 34052504
[TBL] [Abstract][Full Text] [Related]
30. β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
Wang Z; Zhan Y; Xu J; Wang Y; Sun M; Chen J; Liang T; Wu L; Xu K
J Agric Food Chem; 2020 Mar; 68(12):3850-3858. PubMed ID: 32167760
[TBL] [Abstract][Full Text] [Related]
31. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
32. Involvement of Met receptor pathway in aggressive behavior of colorectal cancer cells induced by parathyroid hormone-related peptide.
Novoa Díaz MB; Carriere P; Gigola G; Zwenger AO; Calvo N; Gentili C
World J Gastroenterol; 2022 Jul; 28(26):3177-3200. PubMed ID: 36051345
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
34. Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
Chen MC; Hsu HH; Chu YY; Cheng SF; Shen CY; Lin YJ; Chen RJ; Viswanadha VP; Lin YM; Huang CY
Environ Toxicol; 2018 May; 33(5):587-593. PubMed ID: 29436100
[TBL] [Abstract][Full Text] [Related]
35. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z
Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039
[TBL] [Abstract][Full Text] [Related]
36. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Hu J; Cai G; Xu Y; Cai S
Curr Mol Med; 2016; 16(1):70-82. PubMed ID: 26695693
[TBL] [Abstract][Full Text] [Related]
37. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
38. Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells.
Wang Z; Wang M; Huang J; Lin M; Wei P
Dokl Biochem Biophys; 2024 Apr; 515(1):29-35. PubMed ID: 38189882
[TBL] [Abstract][Full Text] [Related]
39. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
